Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Interleukin-1 signaling contributes to acute islet compensation
Catherine Hajmrle, … , Mourad Ferdaoussi, Patrick E. MacDonald
Catherine Hajmrle, … , Mourad Ferdaoussi, Patrick E. MacDonald
Published April 7, 2016
Citation Information: JCI Insight. 2016;1(4):e86055. https://doi.org/10.1172/jci.insight.86055.
View: Text | PDF
Research Article Inflammation Metabolism

Interleukin-1 signaling contributes to acute islet compensation

  • Text
  • PDF
Abstract

IL-1β is a well-established inducer of both insulin resistance and impaired pancreatic islet function. Despite this, findings examining IL-1 receptor deficiency or antagonism in in vivo animal models, as well as in clinical studies of type 2 diabetic (T2D) patients, have led to conflicting results, suggesting that the actions of IL-1β on glycemic control may be pleiotropic in nature. In the present work, we find that the ability of IL-1β to amplify glucose-stimulated insulin secretion from human islets correlates with donor BMI. Islets from obese donors are sensitized to the insulinotropic effects of this cytokine, whereas the stimulatory effects of IL-1β are lost in islets from obese T2D patients, suggesting a role for IL-1 signaling in islet compensation. Indeed, mice deficient in IL-1 receptor type I become glucose intolerant more rapidly than their WT littermates and have impaired secretory responses during the acute stages of inflammatory and metabolic stress induced by LPS and high-fat diet, respectively. IL-1β directly enhances β cell insulin secretion by increasing granule docking and soluble N-ethylmaleimide-sensitive factor attachment receptor (SNARE) complex formation at the plasma membrane. Together, our study highlights the importance of IL-1β signaling in islet compensation to metabolic and inflammatory stress.

Authors

Catherine Hajmrle, Nancy Smith, Aliya F. Spigelman, Xiaoqing Dai, Laura Senior, Austin Bautista, Mourad Ferdaoussi, Patrick E. MacDonald

×

Figure 2

The stimulatory effect of IL-1β is downstream of intracellular Ca2+.

Options: View larger image (or click on image) Download as PowerPoint
The stimulatory effect of IL-1β is downstream of intracellular Ca2+.
(A)...
(A) Representative (left) and quantified (right) traces of Ca2+ currents obtained by a single depolarization from –70 to 0 mV in dispersed mouse β cells treated with vehicle or IL-1β (10 ng/ml) in the presence of either 2.8 or 16.7 mmol/l glucose (n = 27, 16, 24, 36 cells; 3 experiments). (B) Responses in intracellular Ca2+ ([Ca2+]i) from mouse islets following preincubation with IL-1β (10 ng/ml) for 4 hours (4h + IL-1β) or with acute IL-β treatment (0h + IL-1β) in conjunction with glucose stimulation (arrow; top). Change in area under the curve (ΔAUC) of [Ca2+]i responses (bottom left) (n = 8, 8, 8 islets; 3 experiments) and fold increase in glucose-stimulated [Ca2+]i (GSCa) responses (bottom right) (n = 8, 8, 8 islets; 3 experiments). n values correspond to data points from left to right, respectively. Data are mean ±SEM and were compared with (A) 2-way or (B) 1-way ANOVA followed by (A and B) Tukey post-test. *P < 0.05, **P < 0.01, as indicated.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts